CardioFocus reports controlled commercial launch of the HeartLight System in the US.

M2 EQUITYBITES-November 30, 2017-CardioFocus reports controlled commercial launch of the HeartLight System in the US

(C)2017 M2 COMMUNICATIONS https://www.m2.com

Medical company CardioFocus Inc on Wednesday announced the execution of the successful controlled launch of the HeartLight System for the treatment of paroxysmal atrial fibrillation (AF).

Following the controlled launch, about ten leading cardiac centres across the US have initiated the company's HeartLight programmes.

According to the company, the HeartLight Endoscopic Ablation System is a revolutionary catheter ablation technology designed for the treatment of AF, the most common heart arrhythmia. More than 4,500 patients with AF have been successfully treated with the system. The physician experience with the system has been positive, with users affirming their excitement about the technology's unique features.

The company said the HeartLight System is a visually guided laser balloon technology for controlled and consistent pulmonary vein isolation (PVI) treatment of AF. Its direct visualisation, titratable laser energy and universal balloon design make it a new standard for PVI procedures. It provides an effective and safe treatment option for patients whose heart arrhythmias are insufficiently controlled with medication.

Through the company's direct efforts, product awareness, training and customer adoption of the HeartLight System, the team has established a robust pipeline of more than 100 additional US cardiology centres that have noted a strong interest in initiating the programmes.

((Comments on this story may be sent to [email protected]))